Article

Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection.

Graduate Institute of Biomedical Sciences, Chang Gung University, Tao-Yuan, Taiwan.
PLoS ONE (Impact Factor: 3.53). 05/2011; 6(5):e20029. DOI: 10.1371/journal.pone.0020029
Source: PubMed

ABSTRACT To discover novel markers for improving the efficacy of pancreatic cancer (PC) diagnosis, the secretome of two PC cell lines (BxPC-3 and MIA PaCa-2) was profiled. UL16 binding protein 2 (ULBP2), one of the proteins identified in the PC cell secretome, was selected for evaluation as a biomarker for PC detection because its mRNA level was also found to be significantly elevated in PC tissues.
ULBP2 expression in PC tissues from 67 patients was studied by immunohistochemistry. ULBP2 serum levels in 154 PC patients and 142 healthy controls were measured by bead-based immunoassay, and the efficacy of serum ULBP2 for PC detection was compared with the widely used serological PC marker carbohydrate antigen 19-9 (CA 19-9).
Immunohistochemical analyses revealed an elevated expression of ULPB2 in PC tissues compared with adjacent non-cancerous tissues. Meanwhile, the serum levels of ULBP2 among all PC patients (n = 154) and in early-stage cancer patients were significantly higher than those in healthy controls (p<0.0001). The combination of ULBP2 and CA 19-9 outperformed each marker alone in distinguishing PC patients from healthy individuals. Importantly, an analysis of the area under receiver operating characteristic curves showed that ULBP2 was superior to CA 19-9 in discriminating patients with early-stage PC from healthy controls.
Collectively, our results indicate that ULBP2 may represent a novel and useful serum biomarker for pancreatic cancer primary screening.

Download full-text

Full-text

Available from: Chih-Ching Wu, Jun 27, 2015
0 Followers
 · 
174 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bone is the one of the most common sites of distant metastasis of solid tumors. Secreted proteins are known to influence pathological interactions between metastatic cancer cells and the bone stroma. To comprehensively profile secreted proteins associated with bone metastasis, we used quantitative and non-quantitative mass spectrometry to globally analyze the secretomes of nine cell lines of varying bone metastatic ability from multiple species and cancer types. By comparing the secretomes of parental cells and their bone metastatic derivatives, we identified the secreted proteins that were uniquely associated with bone metastasis in these cell lines. We then incorporated bioinformatic analyses of large clinical metastasis datasets to obtain a list of candidate novel bone metastasis proteins of several functional classes that were strongly associated with both clinical and experimental bone metastasis. Functional validation of selected proteins indicated that in vivo bone metastasis can be promoted by high expression of (1) the salivary cystatins CST1, CST2, and CST4; (2) the plasminogen activators PLAT and PLAU; or (3) the collagen functionality proteins PLOD2 and COL6A1. Overall, our study has uncovered several new secreted mediators of bone metastasis and therefore demonstrated that secretome analysis is a powerful method for identification of novel biomarkers and candidate therapeutic targets.
    Cell Research 06/2012; 22(9):1339-55. DOI:10.1038/cr.2012.89 · 11.98 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bone metastasis is a frequent complication of breast cancer and a common cause of morbidity and mortality from the disease. During metastasis secreted proteins play crucial roles in the interactions between cancer cells and host stroma. To characterize the secreted proteins that are associated with breast cancer bone metastasis, we preformed a label-free proteomic analysis to compare the secretomes of four MDA-MB-231 (MDA231) derivative cell lines with varied capacities of bone metastasis. A total of 128 proteins were found to be consistently up-/down-regulated in the conditioned medium of bone-tropic cancer cells. The enriched molecular functions of the altered proteins included receptor binding and peptidase inhibition. Through additional transcriptomic analyses of breast cancer cells, we selected cystatin E/M (CST6), a cysteine protease inhibitor down-regulated in bone-metastatic cells, for further functional studies. Our results showed that CST6 suppressed the proliferation, colony formation, migration and invasion of breast cancer cells. The suppressive function against cancer cell motility was carried out by cancer cell-derived soluble CST6. More importantly, ectopic expression of CST6 in cancer cells rescued mice from overt osteolytic metastasis and deaths in the animal study, while CST6 knockdown markedly enhanced cancer cell bone metastasis and shortened animal survival. Overall, our study provided a systemic secretome analysis of breast cancer bone tropism and established secreted CST6 as a bona fide suppressor of breast cancer osteolytic metastasis.
    Cell Research 06/2012; 22(9):1356-73. DOI:10.1038/cr.2012.90 · 11.98 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Inflammasomes are cytoplasmic receptors that can recognize intracellular pathogens or danger signals and are critical for IL-1β production. Although several key components of inflammasome activation have been identified, there has not been a systematic analysis of the protein components found in the stimulated complex. In this study, we used the isobaric tags for relative and absolute quantification (iTRAQ) approach to systemically analyze the interactomes of the NLRP3, AIM2, and RIG-I inflammasomes in NPC cells treated with specific stimuli of these interactomes (H2O2, poly (dA:dT) and EBER, respectively). We identified a number of proteins that appeared to be involved in the interactomes and also could be precipitated with anti-ASC antibodies after stimulation. Among them, EB1 was an interacting component in all three interactomes. Silencing of EB1 expression by small interfering RNA inhibited the activation of the three inflammasomes, as indicated by reduced levels of IL-1β secretion. We confirmed that EB1 directly interacted with AIM2 and ASC in vitro and in vivo. Most importantly, fluorescence confocal microscopy showed that EB1 was required for formation of the speck-like particles that represent activation of the AIM2 inflammasome. In NPC tissues, IHC staining showed that EB1 expression was elevated and significantly correlated with AIM2 and ASC expression in NPC tumor cells. In sum, we profiled the interactome components of three inflammasomes and show for the first time that EB1 is crucial for the speck-like particle formation that represents activated inflammasomes.
    Molecular &amp Cellular Proteomics 08/2012; DOI:10.1074/mcp.M112.020594 · 7.25 Impact Factor